PROCTER & GAMBLE HEALTH
|
|
BOM : 500126 NSE : PGHL | |
LT :
Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :
Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Apr 01,2025 |
Price(EOD): ₹ 5,152.30
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 8,552.82 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
PROCTER & GAMBLE HEALTH | -4.8% | -3.3% | 8.7% |
SUN PHARMACEUTICAL INDUSTRIES | -3.9% | 3% | 7.9% |
DIVIS LABORATORIES | -5% | -1.1% | 71.6% |
CIPLA | -4.4% | 0.2% | -1.7% |
TORRENT PHARMACEUTICALS | -1.6% | 6.5% | 26.2% |
DR REDDYS LABORATORIES | -2.4% | 2.4% | -5.4% |
MANKIND PHARMA | 2.4% | 7.1% | 3.9% |
ZYDUS LIFESCIENCES | -3.3% | -1% | -11.4% |
LUPIN | -5.4% | 3.4% | 26.8% |
FUNDAMENTAL ANALYSIS OF PROCTER & GAMBLE HEALTH
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF PROCTER & GAMBLE HEALTH
Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
36.15
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 236.57 Cr
[Latest Qtr - Dec2024 - Standalone Results ] 16.15
P/B Calculated based on Book Value of Rs 529.71 Cr
[Latest Year - Jun2024 - Standalone Results ] 7.38
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
86% 107% 58% |
SHARE PRICE MOMENTUM OF PROCTER & GAMBLE HEALTH
PROCTER & GAMBLE HEALTH vs SENSEX
DEBT OF PROCTER & GAMBLE HEALTH
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Jun2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF PROCTER & GAMBLE HEALTH
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF PROCTER & GAMBLE HEALTH
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-1.16% 8.23% 9.24% 10.41% |
-0.06% 21.43% 22.03% 26.13% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
PROCTER & GAMBLE HEALTH related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE ALLCAP | 1.5% | 3.4% | 7.5% |
BSE 500 SHARIAH | -0.2% | 1.8% | 0.3% |
BSE MIDSMALLCAP | -1.1% | 3.4% | 8.1% |
BSE 500 | -2.2% | 3.2% | 4.8% |
BSE SMALLCAP | -2.5% | 3.6% | 9.2% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MIDSMALL HEALTHCARE | -3% | 5.1% | 24.7% |
You may also like the below Video Courses
FAQ about PROCTER & GAMBLE HEALTH
Is PROCTER & GAMBLE HEALTH good for long term investment?
As on Apr 01,2025, the Fundamentals of PROCTER & GAMBLE HEALTH look Strong and hence it may be good for long term investment! See Financial Performance of PROCTER & GAMBLE HEALTH . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is PROCTER & GAMBLE HEALTH UnderValued or OverValued?
As on Apr 01,2025, PROCTER & GAMBLE HEALTH is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of PROCTER & GAMBLE HEALTH ?
As on Apr 01,2025, the Intrinsic Value of PROCTER & GAMBLE HEALTH is Rs. 2,772.19 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2,772.19
Fair Value [Median EV / Sales Model] : Rs. 2,488.64
Fair Value [Median Price / Sales Model] : Rs. 3,260.79
Estimated Median Fair Value of PROCTER & GAMBLE HEALTH : Rs. 2,772.19
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.